Repatha

THOUSAND OAKS, Calif. – November 10, 2026 -- Amgen reported that an independent health economic analysis of its PCSK9 inhibitor Repatha (evolocumab) found the drug cost-effective at approximately 36% below the ACC/AHA benchmark in high-risk patients with no prior heart attack or stroke. The company presented the data at the American Heart Association (AHA) Scientific Sessions 2026.

Duke-led analysis uses patient-level VESALIUS-CV data

The Duke Clinical Research Institute led the study with the TIMI Study Group at Mass General Brigham and Harvard. It is the first independent health economic analysis built on individual-participant data from the Phase 3 VESALIUS-CV trial, and it compared treatment costs with projected health benefits. A separate analysis found that adding Repatha to standard therapy was highly cost-effective versus standard therapy alone in adults with atherosclerotic cardiovascular disease (ASCVD).

THOUSAND OAKS – November 06, 2026 -- Amgen reported that Repatha (evolocumab) lowered the risk of fatal or nonfatal heart attack by 20% compared with ezetimibe in adults with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The real-world study followed 544,103 patients for up to four years and was published in The American Journal of Preventive Cardiology.

Four-year heart attack risk falls to 5.88% with Repatha versus 7.76% with ezetimibe

Among 225,048 patients with a baseline LDL-C measurement, the four-year cumulative risk of heart attack was 5.88% on Repatha and 7.76% on ezetimibe. Among patients without a baseline LDL-C measurement, the corresponding risks were 5.65% and 7.06%.

The primary outcome was fatal or nonfatal myocardial infarction. The hazard ratio was 0.80 (95% CI, 0.70-0.91).

MUNICH, Germany -- September 02, 2026 -- Amgen's Repatha (evolocumab) reduced all-cause mortality by 20% in high-risk patients who had never suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial presented at the European Society of Cardiology Congress 2026 and published simultaneously in Circulation.

Trial data show mortality benefit emerging after 18 months of treatment

THOUSAND OAKS, Calif. -- September 01, 2026 -- Amgen said its cholesterol drug Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults who had not yet suffered a heart attack or stroke, based on a pre-specified analysis of the Phase 3 VESALIUS-CV trial. The company presented the data in a late-breaking session at the European Society of Cardiology Congress 2026 in Munich, Germany, and published the findings simultaneously in Circulation. Amgen said the result marks the first time a PCSK9 inhibitor has shown a reduction in all-cause mortality among primary prevention patients in a Phase 3 study.